ADC Payload (ADC Cytotoxin)

Maytansinoid DM4 is a thiol-containing maytansine derivative that serves as a potent cytotoxic agent. Acting as a key component in antibody-drug conjugates (ADCs), it exhibits significant biological activity by selectively targeting and destroying cancer cells. This compound is instrumental in advancing therapeutic strategies for cancer treatment research.

(1R,9S)-Dxd is an isomer of Dxd and serves as an antibody-drug conjugate (ADC) payload. Its primary mechanism involves targeted delivery of cytotoxic agents, enhancing the specificity and efficacy of ADCs in cancer therapy. This compound is utilized in the synthesis of various ADC formulations for research applications focused on improving therapeutic outcomes in oncology.

INX-SM-56 is a cytotoxin specifically designed for the synthesis of anti-VISTA antibody-drug conjugates. Targeting VISTA (V-region Immunoglobulin-containing Suppressor of T cell Activation), this compound enhances the cytotoxic efficacy of therapeutic antibodies. It is primarily utilized in cancer research to investigate immune modulation and therapeutic strategies against tumor progression.

DMEA-PNU-159682 is an antibody-drug conjugate (ADC) cytotoxin that combines the metabolites of nemorubicin (MMDX) with the potent cytotoxic agent PNU-159682. This compound exhibits significant cytotoxicity, making it a valuable tool for targeted cancer therapies. Its unique mechanism of action allows for selective delivery of cytotoxic agents to tumor cells, thereby enhancing therapeutic efficacy while minimizing off-target effects in research applications focused on ADC development and optimization.

DC4 is an ADC cytotoxin utilized in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates targeted cancer therapy, enabling the selective delivery of cytotoxic agents to malignant cells while minimizing effects on healthy tissue. Its applications are particularly relevant in oncology research focused on enhancing the efficacy of cancer treatments through targeted delivery mechanisms.

DC4SMe is a phosphate proagent of the cytotoxic DNA alkylator DC4, designed for use in the synthesis of antibody-drug conjugates (ADCs). Exhibiting low IC50 values of 1.9 nM, 2.9 nM, and 1.8 nM against Ramos, Namalwa, and HL60/s cancer cell lines, respectively, DC4SMe demonstrates potent anti-cancer activity. This compound is suitable for research applications focused on targeted cancer therapies.

Diacetyl Agrochelin is an acetyl derivative of Agrochelin, targeting ADC cytotoxins for therapeutic applications. This compound demonstrates significant cytotoxic activity in various tumor cell lines, making it valuable for cancer research and development of targeted anticancer therapies. Its unique mechanism of action supports investigations into the efficacy of antibody-drug conjugates in oncological studies.

TNF-α Agonistic 2 is an agonist targeting tumor necrosis factor-alpha (TNF-α), functioning primarily as an antibody-drug conjugate (ADC) payload. This compound exhibits significant biological activity by reducing tissue thickness, as evidenced by its effects on murine models. It is applicable in research related to targeted cancer therapies and may facilitate the study of TNF-α's role in immune modulation and tumor microenvironment interactions.

Auristatin S is a potent antitumor agent designed as a payload for antibody-drug conjugates (ADCs). It exhibits significant cytotoxic activity while mitigating bystander effects and enhancing off-target toxicity profiles. Auristatin S demonstrates excellent tolerability in Karpas and KarpasBVR cell models, making it a valuable tool for targeted cancer therapies across various tumor types. Its unique properties support its application in the development of effective ADCs for cancer treatment research.

DMEA-PNU-159682 dichloroacetate acts as an antibody-drug conjugate (ADC) cytotoxin, incorporating metabolites of nemorubicin (MMDX) generated from liver microsomes along with the potent cytotoxic agent PNU-159682. This compound exhibits significant biological activity by selectively targeting cancer cells, enabling targeted delivery and enhanced therapeutic efficacy. DMEA-PNU-159682 is applicable in cancer research, specifically in studies focusing on ADC development and the evaluation of cytotoxic mechanisms.

Gly-Cyclopropane-Exatecan functions as a key component in the synthesis of antibody-drug conjugates (ADCs) targeting B7-H4. It incorporates Exatecan, a potent DNA Topoisomerase I inhibitor, into the ADC hu2F7-Exatecan, which has demonstrated significant antitumor efficacy in vivo and in vitro. This compound is relevant for cancer research, particularly in the development of targeted therapy strategies against tumor cells expressing B7-H4.

Muscotoxin A is an ADC cytotoxin that functions as a cytotoxic lipopeptide. It effectively permeabilizes mammalian cell membranes, leading to the induction of necrotic cell death. This compound is valuable in research applications involving targeted cancer therapies and the study of cellular responses to membrane disruption.

Dimethyl-SGD-1882 is a highly potent DNA alkylator, specifically designed for use as an antibody-drug conjugate (ADC) cytotoxin. It acts by forming covalent bonds with DNA, leading to the inhibition of DNA replication and subsequent induction of cytotoxicity in rapidly dividing cancer cells. This compound is valuable for research applications focused on targeted cancer therapies and the development of novel ADCs.

7-MAD-MDCPT TFA is a Camptothecin analog that serves as a cytotoxic payload for antibody-drug conjugates (ADCs). Its mechanism targets topoisomerase I, leading to the induction of apoptosis in malignant cells. This compound is relevant for research applications focused on cancer therapy, particularly in the development of targeted treatment strategies that enhance the efficacy of ADCs.

DUBA is a potent DNA alkylating agent that serves as an effective antibody-drug conjugate (ADC) payload. By covalently binding to DNA, DUBA disrupts replication and transcription processes, leading to cytotoxic effects in targeted cancer cells. Its application in synthesizing ADCs enables enhanced specificity and efficacy in delivering therapeutic agents directly to tumor sites, aiding in cancer research and treatment development.

Cryptophycin analog 1 is a potent antibody-drug conjugate (ADC) payload that targets and disrupts cancer cell proliferation. Exhibiting significant anticancer activity, this compound demonstrates cellular efficacy that is an order of magnitude greater than established ADC payloads such as MMAE and DM1. Its enhanced potency makes it a valuable tool for research in targeted cancer therapies.

NMS-P528 is a Duocarmycin derivative that functions as an antibody-drug conjugate (ADC) payload. This compound exhibits potent cytotoxic activity, providing a mechanism to selectively target and eliminate cancer cells. It can also be utilized in the synthesis of NMS-P945, facilitating advanced research in targeted therapeutic strategies. Its role in ADC development underscores its significance in cancer research applications.

N-MeVal-Val-Dil-Dap-2-(pyridin-3-yl)ethanamine functions as a tubulin polymerization inhibitor and serves as an effective antibody-drug conjugate (ADC) payload. This compound disrupts microtubule dynamics, which can lead to cancer cell apoptosis. Its application in ADC development is valuable for targeted cancer therapies, enhancing the efficacy of specific antibodies against tumor cells.

Azonafide-PEABA is a cytotoxic agent specifically designed for use in antibody-drug conjugates (ADCs). This compound exhibits potent antitumor activity through its ability to interfere with cellular processes, leading to apoptosis in targeted cancer cells. Azonafide-PEABA is ideal for research applications focused on the development and optimization of ADC therapies in oncology.

7-Methylol-9-methoxy-10-F-camptothecin is a camptothecin derivative that serves as a cytotoxic payload for antibody-drug conjugates (ADCs). This compound exhibits potent antitumor activity by inhibiting topoisomerase I, leading to DNA damage and subsequent cancer cell death. Its utility in ADC synthesis makes it a valuable tool for targeted cancer therapy research and development.

NH2-methylpropanamide-Exatecan TFA is a methylpropanamide-modified form of Exatecan, an effective ADC cytotoxin targeting DNA topoisomerase I. With an IC50 of 2.2 μM, this compound plays a crucial role in cancer research by facilitating the development of antibody-drug conjugates (ADCs) for targeted therapies. The modification enhances its utility in the synthesis of ADCs, making it a valuable reagent for studies focused on therapeutic interventions in oncology.

INX-SM-6 is a potent ADC cytotoxin that selectively targets and inhibits the production of pro-inflammatory cytokines. It effectively reduces LPS-induced IL-1β production in human peripheral blood mononuclear cells (PBMCs), making it valuable for research focused on inflammation and immune response modulation. This reagent is suitable for studies aimed at developing targeted therapies for inflammatory diseases.

MMAF-methyl ester functions as an ADC (antibody-drug conjugate) cytotoxin by delivering potent therapeutic agents directly to target cells. This compound exhibits significant cytotoxic activity, disrupting cellular processes and inducing apoptosis in cancer cells. It is primarily utilized in research applications focusing on the development and optimization of targeted cancer therapies, enhancing the efficacy of antibody-based treatments.

Corixetan is a potent thorium chelator utilized in antibody-drug conjugate (ADC) applications. It effectively forms stable complexes with Th-227, providing adequate in vivo stability for targeted cytotoxic delivery. This compound is valuable for research in ADC development and radiotherapy, specifically aiming to improve therapeutic outcomes in cancer treatment.

10NH2-11F-Camptothecin TFA is a derivative of Camptothecin designed for use as an antibody-drug conjugate (ADC) cytotoxin. This compound exhibits potent anticancer activity, making it suitable for the development of targeted cancer therapeutics. Its application in ADC formulation allows for enhanced specificity and efficacy in targeting tumor cells.

Dov-Val-Dil-OH is an antibody-drug conjugate (ADC) cytotoxin designed for targeted cancer therapy. It exhibits potent cytotoxic activity by selectively killing tumor cells upon internalization. This compound is primarily utilized in the development and evaluation of ADCs, allowing researchers to study its efficacy in various cancer models.

Exatecan-2-(aminomethoxy)acetamide-Gly-Fmoc is an antibody-drug conjugate (ADC) cytotoxin designed for targeted cancer therapy. This compound exerts its cytotoxic effects primarily through the inhibition of topoisomerase I, leading to DNA damage and subsequent cell death in malignant cells. It is utilized in research for the development of innovative ADCs, optimizing delivery mechanisms for enhanced tumor selectivity and therapeutic efficacy.

Modified MMAF is an ADC cytotoxin that functions by disrupting microtubule dynamics, leading to cell cycle arrest and apoptosis in cancer cells. It is primarily utilized in the synthesis of Antibody-drug Conjugates (ADCs), enhancing the specificity and efficacy of targeted cancer therapies. This compound is a valuable tool for research applications focused on cancer treatment modalities and the development of targeted drug delivery systems.